Background: Omalizumab is an anti-IgE therapy newly approved by the Food and Drug Administration for allergen agnostic treatment of single or multiple food allergies in patients aged 1 year or older.
Objective: Evaluate the cost-effectiveness of omalizumab as a food allergy treatment.
Methods: We evaluated health and economic outcomes in Markov cohorts of simulated food allergic infants randomized to receive omalizumab using a 15-year horizon. Monte Carlo simulation was used (n = 40,000 subjects) to evaluate cost-effectiveness from a societal perspective, incorporating both a family-level and individual-level analysis. We included family-level analysis to incorporate a broad perspective for health utility change, given treatment effects likely benefit all parties at home (eg, caregivers, siblings), not just the patient, representing the sum of changes in all such persons. Supplemental analyses explored lower omalizumab cost and home initiation. We performed deterministic and probabilistic sensitivity analyses.
Results: In the family-level cohort analysis, omalizumab exceeded cost-effectiveness thresholds ($185,183/quality-adjusted life-years [QALY]). In a comparison of the omalizumab strategy (OMA) with the non-omalizumab strategy, the cost of OMA exceeded the non-omalizumab strategy ($315,020 vs $136,609) with greater incremental effectiveness (12.668 vs 11.699 QALY). In the individual-level analysis, the cost-effectiveness of OMA was $573,698/QALY. In base-case assessments, OMA was cost-effective (willingness to pay, $100,000/QALY) at a health state utility (HSU) improvement of 0.265. The value-based cost of OMA ranged from $14,166 to $23,791 when it was considered at the individual and family-unit levels. Requiring OMA administration in the clinic was not cost-effective (incremental cost-effectiveness ratio, $260,239).
Conclusions: In the base case and at current pricing, omalizumab is not cost-effective, but it could be at a lower retail price or when use creates large health utility shifts in the family and patient.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jaip.2024.06.023 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Olfactory Dysfunction in Chronic Rhinosinusitis with Nasal Polyps: Effect of Treatment with Emphasis on Biological Therapy.
Curr Allergy Asthma Rep
November 2024
Amsterdam UMC, Department of Otorhinolaryngology & Head and Neck Surgery, University of Amsterdam, Meibergdreef 9, D2-233, Postbus 22660, Amsterdam Zuidoost , 1100 DD, The Netherlands.
Purpose Of Review: Olfactory dysfunction significantly impacts quality of life that affects a majority of the patients with chronic rhinosinusitis with nasal polyps (CRSwNP). The aim of this review is to explore the impact of various treatment regimens on olfactory dysfunction in patients diagnosed with CRSwNP.
Recent Findings: Accurate assessment of olfactory dysfunction remains challenging and should incorporate both psychophysical tests and patient-reported outcomes.
Comparison of long term efficacy and cost-effectiveness of omalizumab in 150 mg and 300 mg doses in patients with chronic spontaneous urticaria.
An Bras Dermatol
January 2025
Department of Immunology and Allergy, University of Health Sciences, Gulhane Training and Research Hospital, Ankara, Turkey.
Article Synopsis
- Chronic spontaneous urticaria (CSU) negatively impacts patients' quality of life, and omalizumab is recommended for cases resistant to antihistamines; the Urticaria Activity Score-7 (UAS-7) measures disease severity.* -
- A study compared the long-term effectiveness and side effects of two doses (150 mg and 300 mg) of omalizumab in 108 CSU patients over 60 months, finding no significant differences in disease scores or adverse events between groups.* -
- The research concluded that starting with a 150 mg dose is adequate for CSU treatment, with an option to increase to 300 mg if needed, offering a potentially safer and more
Cost and Cost-Effectiveness of the Management Strategies of Chronic Urticaria: A Systematic Review.
JAMA Dermatol
November 2024
Pharmacoepidemiology and Statistics Research Center (PESRC), Faculty of Pharmacy, Chiang Mai University, Chiang Mai, Thailand.
Article Synopsis
- The text discusses the importance of understanding the costs and effectiveness of treatment strategies for chronic urticaria (CU), highlighting a gap in evidence regarding their net benefits.
- The objective was to summarize the costs and cost-effectiveness of various CU management strategies, supported by a comprehensive literature search across multiple databases.
- Findings showed that using the biologic omalizumab for treatment resulted in higher annual healthcare costs compared to other management strategies, with notable variations in cost-effectiveness ratios per quality-adjusted life year (QALY).
Evaluating the Efficacy of Omalizumab in Severe Cedar Seasonal Allergic Rhinitis in Japan.
Cureus
July 2024
Otolaryngology, Osaka Metropolitan University, Osaka, JPN.
Traditional treatments for cedar seasonal allergic rhinitis include second-generation antihistamines, nasal corticosteroids, and sublingual immunotherapy (SLIT). Omalizumab (Xolair®), an anti-immunoglobulin E (IgE) monoclonal antibody, is an additional option for severe cases unresponsive to existing therapies. Numerous studies have demonstrated the therapeutic effectiveness of omalizumab for cedar seasonal allergic rhinitis; however, most reported results after only up to four weeks of follow-up.
View Article and Find Full Text PDFChronic Spontaneous Urticaria: Quality of Life and Economic Impacts.
Immunol Allergy Clin North Am
August 2024
Division of Allergy and Clinical Immunology, University of Colorado School of Medicine, 12700 East 19th Avenue 10C03, Aurora, CO 80045, USA.
Article Synopsis
- * New assessment tools, such as the Urticaria Activity and Impact Measure, aim to provide a comprehensive evaluation of how the condition affects patients' daily lives.
- * The research highlights not only the emotional and psychological struggles associated with chronic urticaria but also the increasing healthcare costs and the economic considerations of treatments like omalizumab.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!